Investigational agents for the irritable bowel syndrome.
BACKGROUND
Irritable bowel syndrome (IBS) is a common disorder with significant health and economic consequences. The etiology of IBS is complex and appears to be multifactorial. Traditional IBS therapies have been directed primarily at the relief of individual symptoms but have been largely disappointing. This has triggered the search for newer treatment strategies with improved patient outcomes.


METHODS
Enhanced knowledge about the putative pathophysiology of IBS has allowed the identification of new mechanistic targets for treatment. Our aim is to review emerging and promising drugs in the treatment of IBS based on disease pathophysiology. Data were extracted using Medline and PubMed search engines until January 2010. Abstracts were identified through 'Web of Science' and abstract supplements of major gastrointestinal scientific meetings. Drugs were classified according to mechanism of action and those with efficacy in trials involving human subjects examined.


RESULTS
Additional insight into the pathophysiology as well as current and prospective treatments of IBS.


CONCLUSIONS
A multitude of putative drug targets have been identified and some novel treatments have progressed through to human clinical trials, but very few will be approved for the market in the near future. Moreover, and in keeping with the complex and multifactorial nature of this syndrome, it is unlikely that there will be one dominant and universally effective form of therapy for all IBS patients.
Ghaith
Ola
O
Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
El-Halabi
Mustapha
M
Hashash
Jana G
JG
Sharara
Ala I
AI
D000588:Amines / Q000494:pharmacology / Q000627:therapeutic use; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000627:therapeutic use*; D005260:Female; D000077206:Gabapentin; D005765:Gastrointestinal Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D043183:Irritable Bowel Syndrome / Q000188:drug therapy* / Q000503:physiopathology*; D008297:Male; D008550:Melatonin / Q000494:pharmacology / Q000627:therapeutic use; D058990:Molecular Targeted Therapy; D009292:Narcotic Antagonists; D009414:Nerve Growth Factors / Q000494:pharmacology / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D011949:Receptors, Cholecystokinin / Q000037:antagonists & inhibitors; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D050705:Receptors, Guanylate Cyclase-Coupled / Q000819:agonists / Q000187:drug effects / Q000494:pharmacology; D011957:Receptors, Opioid / Q000819:agonists; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology / Q000627:therapeutic use; D000099052:CRF Receptor, Type 1
D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D015507:Drugs, Investigational; D005765:Gastrointestinal Agents; D009292:Narcotic Antagonists; D009414:Nerve Growth Factors; D018377:Neurotransmitter Agents; D011949:Receptors, Cholecystokinin; D018019:Receptors, Corticotropin-Releasing Hormone; D011957:Receptors, Opioid; D005680:gamma-Aminobutyric Acid; D000099052:CRF Receptor, Type 1; D000077206:Gabapentin; D050705:Receptors, Guanylate Cyclase-Coupled; D008550:Melatonin